Size-specific dose estimates for adult patients at CT of the torso.

PURPOSE: To determine relationships among patient size, scanner radiation output, and size-specific dose estimates (SSDEs) for adults who underwent computed tomography (CT) of the torso. MATERIALS AND METHODS: Informed consent was waived for this institutional review board-approved study of existing data from 545 adult patients (322 men, 223 women) who underwent clinically indicated CT of the torso between April 1, 2007, and May 13, 2007. Automatic exposure control was used to adjust scanner output for each patient according to the measured CT attenuation. The volume CT dose index (CTDI(vol)) was used with measurements of patient size (anterioposterior plus lateral dimensions) and the conversion factors from the American Association of Physicists in Medicine Report 204 to determine SSDE. Linear regression models were used to assess the dependence of CTDI(vol) and SSDE on patient size. RESULTS: Patient sizes ranged from 42 to 84 cm. In this range,CTDI(vol) was significantly correlated with size (slope = 0.34 mGy/cm; 95% confidence interval [CI]: 0.31, 0.37 mGy/cm; R(2) = 0.48; P < .001), but SSDE was independent of size (slope = 0.02 mGy/cm; 95% CI: -0.02, 0.07 mGy/cm; R(2) = 0.003; P = .3). These R(2) values indicated that patient size explained 48% of the observed variability in CTDI(vol) but less than 1% of the observed variability in SSDE. The regression of CTDI(vol) versus patient size demonstrated that, in the 42-84-cm range, CTDI(vol) varied from 12 to 26 mGy. However, use of the evaluated automatic exposure control system to adjust scanner output for patient size resulted in SSDE values that were independent of size. CONCLUSION: For the evaluated automatic exposure control system,CTDI(vol) (scanner output) increased linearly with patient size; however, patient dose (as indicated by SSDE) was independent of size.

Levels of phosphodiesterase 4A and 4B are altered by chronic treatment with psychotropic medications in rat frontal cortex.

Our laboratory has recently demonstrated altered expression of phosphodiesterase (PDE) 4A and 4B in subjects with autism, bipolar disorder, and schizophrenia, suggesting disrupted cAMP signaling in these diagnostic groups. In the current study, we measured expression of PDEs in rat frontal cortex (FC) following chronic treatment with clozapine, fluoxetine, haloperidol, lithium, olanzapine, valproic acid (VPA), or sterile saline for 21 days. Western blotting experiments showed decreased expression of PDE4A subtypes in FC following treatment with clozapine, haloperidol, lithium, and VPA. PDE4B subtypes were similarly reduced in FC following treatment with clozapine, fluoxetine, and lithium. We also measured levels of nine PDE subtypes via qRT-PCR in FC and found significant upregulation of PDE1A and PDE8B following treatment with olanzapine, while treatment with lithium reduced expression of mRNA for PDE8B. Our results demonstrate altered expression of PDE4A and PDE4B in response to a variety of psychotropic medications suggesting potentially new therapeutic avenues for treatment of neuropsychiatric diseases.

Dual-source computed tomographic temporal resolution provides higher image quality than 64-detector temporal resolution at low heart rates.

OBJECTIVE: To compare coronary image quality at temporal resolutions associated with dual-source computed tomography (DSCT; 83 milliseconds) and 64-detector row scanning (165 milliseconds). METHODS: In 30 patients with a heart rate of less than 70 beats per minute, DSCT coronary angiograms were reconstructed at 83- and 165-millisecond temporal resolutions over different cardiac phases. A blinded observer graded coronary quality. RESULTS: The typical DSCT temporal resolution (83 milliseconds) showed a significantly greater quality at end-systole for all coronary vessels and at end-diastole for the right coronary and left anterior descending coronary arteries. For all vessels, the end-diastole produced the highest quality for both temporal resolutions. CONCLUSIONS: Imaging at 83 milliseconds creates superior quality at end-systole for all coronary vessels and at end-diastole for the right coronary and left anterior descending coronary arteries. At low heart rates, end-diastole produces the highest quality at both temporal resolutions.

Optimal image reconstruction phase at low and high heart rates in dual-source CT coronary angiography.

The purpose of this study was to determine the cardiac phase having the highest coronary sharpness for low and high heart rate patients scanned with dual source CT (DSCT) and to compare coronary image sharpness over different cardiac phases. DSCT coronary CT scans for 30 low heart rate (< or =70 beats per minute- bpm) and 30 high heart rate (>70 bpm) patients were reconstructed into different cardiac phases, starting at 30% and increasing at 5% increments until 70%. A blinded observer graded image sharpness per coronary segment, from which sharpness scores were produced for the right (RCA), left main (LM), left anterior descending (LAD), and circumflex (Cx) coronary arteries. For each coronary artery, the phase with maximal image sharpness was identified with repeated measures analysis of variance. Comparison of coronary sharpness between low and high heart rate patients was made using generalized estimating equations. For low heart rates the highest sharpness scores for all four vessels (RCA, LM, LAD, and Cx) were at the 65 or 70% phase, which are end-diastolic cardiac phases. For high heart rates the highest sharpness scores were between the 35 and 45% phases, which are end-systolic phases. Low heart rate patients had higher coronary sharpness at most cardiac phases; however, patients with high heart rates had higher coronary sharpness in the 45% phase for all four vessels (P < 0.0001). Using DSCT scanning, optimal image sharpness is obtained in end-diastole at low heart rates and in end-systole in high heart rates.

Chronic psychotropic drug treatment causes differential expression of connexin 43 and GFAP in frontal cortex of rats.

Astrocytic markers glial fibrillary acidic protein (GFAP) and connexin 43 (CX43) are known to have altered expression in brains of subjects with psychiatric disorders including autism and major depression. The current study investigated whether GFAP and CX43 expressions are affected by several commonly used psychotropic medications (clozapine, fluoxetine, haloperidol, lithium, olanzapine, and valproic acid). Using SDS-PAGE and western blotting technique, we observed that CX43 protein expression in prefrontal cortex was significantly increased following chronic treatment with fluoxetine and clozapine, while it was significantly decreased by haloperidol and lithium. GFAP protein expression was significantly decreased following chronic treatment with clozapine and valproic acid. These results suggest that astroglial markers GFAP and CX43 could be potential targets for therapeutic intervention.

Expression of phosphodiesterase 4 is altered in the brains of subjects with autism.

The cyclic adenosine monophosphate-specific phosphodiesterase-4 (PDE4) gene family is the target of several potential therapeutic inhibitors and the PDE4B gene has been associated with schizophrenia and depression. Little, however, is known of any connection between this gene family and autism, with limited effective treatment being available for autism. We measured the expression of PDE4A and PDE4B by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blotting in Brodmann's area 40 (BA40, parietal cortex), BA9 (superior frontal cortex), and cerebellum from subjects with autism and matched controls. We observed a lower expression of PDE4A5, PDE4B1, PDE4B3, PDE4B4, and PDE4B2 in the cerebella of subjects with autism when compared with matched controls. In BA9, we observed the opposite: a higher expression of PDE4AX, PDE4A1, and PDE4B2 in subjects with autism. No changes were observed in BA40. Our results demonstrate altered expressions of the PDE4A and PDE4B proteins in the brains of subjects with autism and might provide new therapeutic avenues for the treatment of this debilitating disorder.

Radiation exposure and pregnancy: when should we be concerned?

The potential biological effects of in utero radiation exposure of a developing fetus include prenatal death, intrauterine growth restriction, small head size, mental retardation, organ malformation, and childhood cancer. The risk of each effect depends on the gestational age at the time of exposure, fetal cellular repair mechanisms, and the absorbed radiation dose level. A comparison between the dose levels associated with each of these risks and the estimated fetal doses from typical radiologic examinations lends support to the conclusion that fetal risks are minimal and, therefore, that radiologic and nuclear medicine examinations that may provide significant diagnostic information should not be withheld from pregnant women. The latter position is advocated by the International Commission on Radiological Protection, National Council on Radiation Protection, American College of Radiology, and American College of Obstetrics and Gynecology. However, although the risks are small, it is important to ensure that radiation doses are kept as low as reasonably achievable.